Table 1.
Baseline characteristics of patients with non-metastatic RCC according to Fib-PNI-MLR score.
| Parameter | Fib-PNI-MLR | ||||
|---|---|---|---|---|---|
| 0 (n = 314) | 1 (n = 258) | 2 (n = 162) | 3 (n = 95) | P value | |
| Age, years (≥65/<65) | 93/221 | 111/147 | 88/74 | 60/35 | <0.001* |
| Age, years | 57.18 ± 11.44 | 60.00 ± 12.08 | 64.29 ± 12.61 | 65.25 ± 13.19 | <0.001* |
| Gender (male/female) | 185/129 | 169/89 | 105/57 | 67/28 | 0.143 |
| ASA grade (1/2/3) | 57/249/8 | 29/210/19 | 15/134/13 | 6/73/16 | <0.001* |
| BMI, kg/m2 (≥25/<25) | 85/229 | 84/174 | 35/127 | 18/77 | 0.022* |
| BMI, kg/m2 | 23.38 ± 3.19 | 23.74 ± 3.31 | 22.98 ± 3.07 | 22.54 ± 2.79 | 0.007* |
| DM (yes/no) | 117/196 | 99/159 | 73/89 | 31/64 | 0.214 |
| Hypertension (yes/no) | 110/204 | 123/135 | 76/86 | 46/49 | 0.006* |
| Anemia (yes/no) | 8/306 | 23/235 | 32/130 | 41/54 | <0.001* |
| Hypoalbuminemia (yes/no) | 2/312 | 18/240 | 35/127 | 41/54 | <0.001* |
| Surgical approach (Partial nephrectomy/Radical nephrectomy) | 90/224 | 88/170 | 33/129 | 10/85 | <0.001* |
| CKD stage (CKD1/CKD2/CKD3/CKD4/CKD5) | 248/64/2/0/0 | 182/68/6/0/2 | 94/54/9/2/3 | 43/33/11/1/7 | <0.001* |
| Pathologic T stage (pT1/pT2/pT3/pT4) | 274/23/15/2 | 205/28/23/2 | 125/21/15/1 | 58/18/15/4 | <0.001* |
| Fuhrman grade (1/2/3/4) | 121/140/48/5 | 89/110/53/6 | 51/66/42/3 | 20/42/27/6 | 0.005* |
| Histologic subtype (Clear cell/Papillary/Chromophobe/Collecting duct/Unclassified) | 271/17/25/0/1 | 226/15/16/0/1 | 136/16/9/0/1 | 81/9/4/1/0 | 0.576 |
| Tumor necrosis (yes/no) | 7/307 | 8/250 | 8/154 | 9/86 | 0.011* |
| Tumor size, cm (≥7/<7) | 33/281 | 41/217 | 34/128 | 33/62 | <0.001* |
| Tumor size, cm | 4.34 ± 2.41 | 4.60 ± 2.78 | 5.21 ± 4.26 | 6.07 ± 4.01 | <0.001* |
| Serum creatinine, mg/dl | 0.75 ± 0.16 | 0.83 ± 0.61 | 1.00 ± 1.25 | 1.61 ± 2.50 | <0.001* |
| BUN, mg/dl | 5.40 ± 1.33 | 5.86 ± 2.19 | 6.24 ± 3.52 | 6.83 ± 4.82 | <0.001* |
| Uric acid, mg/dl | 5.65 ± 1.45 | 5.61 ± 1.52 | 5.56 ± 1.57 | 5.74 ± 1.65 | 0.793 |
| ALT, U/L | 25.09 ± 18.92 | 25.85 ± 22.84 | 27.31 ± 31.40 | 25.16 ± 35.70 | 0.827 |
| AST, U/L | 24.62 ± 11.85 | 25.93 ± 15.09 | 28.13 ± 18.88 | 25.98 ± 18.49 | 0.130 |
| ALP, U/L | 76.59 ± 25.65 | 78.10 ± 25.10 | 80.78 ± 32.07 | 96.34 ± 71.48 | <0.001* |
| Plasma fibrinogen (≥3.54/<3.54), mg/dl | 0/314 | 87/171 | 104/58 | 95/0 | <0.001* |
| WBCs, cells × 103/ul | 6.38 ± 1.79 | 6.36 ± 1.77 | 6.59 ± 2.37 | 7.66 ± 2.66 | <0.001* |
| Neutrophils, cells/ul | 3.68 ± 1.23 | 3.96 ± 1.37 | 4.41 ± 2.19 | 5.30 ± 2.12 | <0.001* |
| Monocytes, cells/ul | 0.40 ± 0.13 | 0.48 ± 0.18 | 0.55 ± 0.21 | 0.68 ± 0.28 | <0.001* |
| Lymphocytes, cells/ul | 2.14 ± 0.99 | 1.77 ± 0.52 | 1.47 ± 0.49 | 1.30 ± 0.38 | <0.001* |
| Platelets, cells × 104/ul | 218.18 ± 60.05 | 215.69 ± 68.73 | 218.10 ± 81.63 | 248.75 ± 83.07 | 0.001* |
| PNI (<47.03/≥47.03) | 0/314 | 58/200 | 85/77 | 95/0 | <0.001* |
| NLR (≥3.30/<3.30) | 15/299 | 36/222 | 52/110 | 54/41 | <0.001* |
| MLR (≥0.29/<0.29) | 0/314 | 113/145 | 135/27 | 95/0 | <0.001* |
| PLR (≥184.16/<184.16) | 18/296 | 32/226 | 46/116 | 51/44 | <0.001* |
| Hemoglobin, g/dl | 138.22 ± 14.53 | 135.81 ± 16.72 | 129.94 ± 17.60 | 118.11 ± 23.88 | <0.001* |
| Albumin, g/L | 43.23 ± 3.56 | 41.70 ± 4.18 | 39.01 ± 5.63 | 35.07 ± 3.88 | <0.001* |
| All-cause death, n (%) | 6/308 | 8/250 | 19/143 | 29/66 | <0.001* |
| Follow-up duration, months, median (quartile) | 55.06 ± 27.69 | 55.27 ± 27.46 | 52.13 ± 28.23 | 49.93 ± 29.69 | 0.294 |
| 5-year OS rate | 97.5% | 97.1% | 86.3% | 66.2% | <0.001* |
| Cancer-specific death, n | 3/311 | 4/254 | 13/149 | 20/75 | <0.001* |
| Follow-up duration, months, median (quartile) | 55.06 ± 27.69 | 55.27 ± 27.46 | 52.13 ± 28.23 | 49.93 ± 29.69 | 0.294 |
| 5-year CSS rate | 98.7% | 98.1% | 89.9% | 74.1% | <0.001* |
| Patients who developed metastasis after surgery, n | 17/297 | 15/243 | 18/144 | 32/63 | <0.001* |
| Follow-up duration, months, median (quartile) | 54.03 ± 27.57 | 53.61 ± 26.95 | 50.57 ± 29.19 | 43.90 ± 31.93 | 0.014* |
| 5-year MFS rate | 95.2% | 94.3% | 89.0% | 61.5% | <0.001* |
*P < 0.05.
RCC, renal cell carcinoma; DM, diabetes mellitus; CKD, chronic kidney disease; OS, overall survival; CSS, cancer-specific survival; MFS, metastatic-free survival; WBC, white blood cell; PNI, prognostic nutritional index; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; ALT, alanine aminotransferase; AST, glutamate aminotransferase; ALP, alkaline phosphatase; BUN, urea nitrogen.